SAN DIEGO, June 10, 2013 /PRNewswire/ -- Verenium Corporation (Nasdaq: VRNM), a leading industrial biotechnology company focused on the development and commercialization of high-performance enzymes, today announced it has named enzyme industry veteran Brian Carter to the new position of Vice President of Grain Processing.
Carter joined Verenium after nearly 20 years at Genencor, now part of DuPont Industrial Biosciences. At Genencor, he held a variety of senior leadership roles in business development and general management. Carter joined Verenium in September, 2012 as a Vice President, Business Development, leading select business development initiatives, including several in the grain processing industry.
Carter's appointment is the latest in a series of organizational enhancements Verenium has made to expand its customer support and market penetration in the grain processing industry.
In another key appointment, Kulinda Davis, Ph.D., has taken on the new role of Director, Business Strategy and Marketing, focused on supporting further penetration of the U.S. market, commercializing new enzyme products, and expanding the Company's international presence in grain processing. In addition, Verenium has recently made key hires in sales, field technical support and in-house customer technical support.
"We are pleased to have Brian leading our grain processing efforts," said Janet Roemer, Chief Operating Officer at Verenium. "Brian and Kulinda's appointments are important steps in building a world class team to support our customers in the U.S. corn ethanol market and in growing our presence in the global grain processing industry."
Verenium, an industrial biotechnology company, is a global leader in developing high-performance enzymes. Verenium's tailored enzymes are environmentally friendly, making products and processes greener and more cost-effective for industries, including the global food and fuel markets. Read more at www.verenium.com.
Statements in this press release that are not strictly historical are "forward-looking" and involve a high degree of risk and uncertainty. These include, but are not limited to, statements related to Verenium's technology, products and product candidates (including, in each case, their value, potential for revenue growth and expected near-term and longer term revenue)and product pipeline (including the timing for commercial launch of any product candidates), lines of business, operations (including Verenium's ability to successfully negotiate and enter into future collaborations and partnerships), capabilities, commercialization activities, customer adoption rates, industry conditions, future financial performance (including all financial guidance), and near-term and longer-term growth and prospects. Such statements are only predictions, and actual events or results may differ materially from those projected in such forward-looking statements. Factors that could cause or contribute to the differences include, but are not limited to, risks associated with Verenium's strategic focus, technologies, products and product candidates and product pipeline (including Verenium's ability to identify, develop and commercialize new products and product candidates, either independently or with collaborators or partners, and market demand for those products and product candidates), dependence on patents and proprietary rights, protection and enforcement of its patents and proprietary rights, the commercial prospects of the industries in which Verenium operates and sells products, Verenium's dependence on manufacturing and/or license agreements, its ability to achieve milestones under existing and future collaboration agreements, the ability of Verenium and its partners to commercialize its technologies and products (including by obtaining any required regulatory approvals) using Verenium's technologies, the timing for launching any commercial products and projects, the ability of Verenium and its collaborators to market and sell any products that it or they commercialize, the development or availability of competitive products or technologies, the future ability of Verenium to enter into and/or maintain collaboration and joint venture or partnership agreements and licenses on a timely basis or at all, and risks and other uncertainties more fully described in Verenium's filings with the Securities and Exchange Commission, including, but not limited to, Verenium's annual report on Form 10-K for the year ended December 31, 2012 and any updates contained in its subsequently filed quarterly reports on Form 10-Q. These forward-looking statements speak only as of the date hereof, and Verenium expressly disclaims any intent or obligation to update these forward-looking statements.
SOURCE Verenium Corporation